Capricor Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CAPR Nasdaq 2836 www.capricor.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Capricor Therapeutics, Inc.

Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls - Jul 30th, 2026 7:38 am
Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel - Jul 30th, 2026 7:30 am
Capricor’s FDA Fate Divides Wall Street And Investors: One Analyst Sees A $2 Stock But Retail Holds Out Hope - Jul 30th, 2026 5:58 am
CAPR Stock Eyes Worst Week Ever After FDA Panel Blow To Deramiocel — Retail Bulls Still See A Path To Approval - Jul 29th, 2026 9:07 pm
Capricor Faces Make-Or-Break FDA Panel For Duchenne Cell Therapy — Experts And Investors Weigh In - Jul 29th, 2026 2:24 pm
Capricor’s DMD Therapy Gets Lancet Backing Ahead Of August FDA Showdown – CEO Says Publication ‘Reinforce Our Confidence’ For Approval - Jul 29th, 2026 10:20 am
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy - Jul 29th, 2026 8:05 am
This Analyst Slashed CAPR Stock’s Target By 86% – But, Retail Bulls Say Setup Offers An Attractive Risk-Reward - Jul 28th, 2026 10:07 am
CAPR Stock Eyes Worst Month In 9 Years On FDA Doubts — ‘Pharma Bro’ Shkreli Piles On, But Retail Turns More Bullish Than Ever - Jul 27th, 2026 8:38 pm
CAPR Stock On Track For Worst Day Ever — Analysts Divided On Deramiocel’s Approval Probability After FDA Documents Paint ‘Ugly Picture’ - Jul 27th, 2026 1:42 pm
Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document - Jul 27th, 2026 9:39 am
Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel - Jul 27th, 2026 9:00 am
Capricor Therapeutics shares tumble after FDA reviewers raise concerns over Duchenne therapy - Jul 27th, 2026 8:50 am
CAPR Stock Is Crashing Today – FDA Briefing Casts Doubt On Duchenne Cell Therapy Before Key Vote - Jul 27th, 2026 7:48 am
Capricor Therapeutics shares plunge after FDA releases briefing documents - Jul 27th, 2026 7:43 am
How FDA‑Linked HQ and Manufacturing Expansion At Capricor Therapeutics (CAPR) Has Changed Its Investment Story - Jul 27th, 2026 6:07 am
FDA scientists question Capricor data; Legend CEO steps down - Jul 27th, 2026 5:00 am
Is Capricor Therapeutics (CAPR) Trading At A Discount After Its Lease Deal And FDA Wait? - Jul 27th, 2026 3:12 am
Capricor Therapeutics (CAPR) Stock Looks Fully Priced For Now - Jul 26th, 2026 6:08 am
This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy? - Jul 25th, 2026 5:31 am